Skip to content

Welcome to Discover Pharma! Today is : November 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Synaffix and Qurient partner on dual-payload ADC for solid tumours

    Lonza’s Synaffix has signed a licensing agreement with Qurient Therapeutics [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    N4 Pharma and SRI demonstrate targeted Nuvec delivery to lung cancer cells

    N4 Pharma has reported new data from its collaboration with [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics

    Acella Pharmaceuticals reports positive Phase 2 results for North Star desiccated thyroid extract

    Acella Pharmaceuticals and Neuvosyn Laboratories have reported positive topline results [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    ReiThera: Commercial CDMO capabilities key to manage ‘volatile’ biotech market

    ReiThera will begin commercial production in 2026, a milestone the [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Persista Bio wins NIH funding to advance O2Line cell therapy

    Persista Bio has been awarded two grants from the US [...]

    May 5, 2026
  • Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gene therapy AMT-130 slows Huntington’s disease progression in early trial

    A gene therapy developed by uniQure appears to slow progression [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg secures free supply of bispecific antibody for POLB 001 trial at The Christie

    Poolbeg Pharma has appointed Accelerating Clinical Trials (ACT) to run [...]

    May 5, 2026
  • Advanced Therapies,Digital & Data,Drug Discovery & Development

    AISB Network expands Federated OpenFold3 initiative with three new pharma contributors

    The AI Structural Biology (AISB) Network, powered by Apheris GmbH, [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    RION partners with Lonza to scale manufacturing of exosome-based therapeutics

    RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Merck opens climate-neutral €150 million filter manufacturing facility in Ireland

    Merck has inaugurated its first climate-neutral manufacturing facility in Ireland, [...]

    May 5, 2026
Previous181920Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Circio raises NOK 200M (€18.6M) to advance in vivo CAR-T programme
    Categories: Advanced Therapies, Biotech & Pharma Business, Research & Development
  • AstraZeneca advances oral COPD drug into Phase 2b trial
    Categories: Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top